Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the systematic treatment enhancement program for bipolar disorder

Journal of Clinical Psychiatry

Volumn 72, Issue 2, 2011, Pages 240-247

  Brooks III, John O ^a   Goldberg, Joseph F ^b,c   Ketter, Terence A ^d   Miklowitz, David J ^e   Calabrese, Joseph R ^f   Bowden, Charles L ^g   Thase, Michael E ^h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SILVER HILL HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g Mays Cancer Center at UT Health San Antonio   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEADACHE; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL HEALTH SERVICE; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC TREATMENT ENHANCEMENT PROGRAM FOR BIPOLAR DISORDER; TREATMENT DURATION; TREMOR; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HEALTH SERVICES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

EID: 79951990744     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05214yel     Document Type: Article

References (36)

1. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry. 2003;64(4):425-432.
2. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness-1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):213-219.
3. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo- controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912. doi:10.176/api.ajp.158.6.906 PubMed (Pubitemid 32547620)
4. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356(17):1711-1722. doi:10.1056/NEJMoa064135 PubMed (Pubitemid 46658703)
5. Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8(1):15-27. doi:10.1/j.139-5618.206.0276.x PubMed (Pubitemid 43356017)
6. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin Bipolar Disorder Study Group. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord. 2000;2(3 Pt 2):249-255.
7. Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2):155-162.
8. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597-1600.
9. Sim K, Su A, Chan YH, et al. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci. 2004;58(3):324-329. doi:10.1/j.140-1819.204.01239.x PubMed (Pubitemid 38859016)
10. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007;58(4):489-495. doi:10.176/api.ps.58.4.489 PubMed (Pubitemid 46640639)
11. Centorrino F, Fogarty KV, Sani G, et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol. 2005;20(7):485-492.
12. Valuck RJ, Morrato EH, Dodd S, et al. Medicaid Pharmacotherapy Research Consortium. How expensive is antipsychotic polypharmacy? experience from five US state Medicaid programs. Curr Med Res Opin. 2007;23(10):2567-2576.
13. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119(6):419-425.
14. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):e1-e12.
15. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130-136. doi:10.176/api.ajp.162.1.130 PubMed (Pubitemid 40095682)
16. Vieta E, Franco C. [Advances in the treatment of mania: aripiprazole]. Actas Esp Psiquiatr. 2008;36(3):158-164.
17. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028-1042. doi:10.1016/S06-323(03)0165-3 PubMed (Pubitemid 36645233)
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
19. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002;4(5):323-327.
20. Otto MW, Simon NM, Wisniewski SR, et al. STEP-BD Investigators. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189(1):20-25. doi:10.192/bjp.bp.104.073 PubMed (Pubitemid 44023325)
21. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4. 382 PubMed (Pubitemid 9136500)
22. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429 PubMed (Pubitemid 9006756)
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1977.
24. Calabrese JR, Elhaj O, Gajwani P, et al. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry. 2005;66(suppl 5):26-33.
25. Gao K, Gajwani P, Elhaj O, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry. 2005;66(11):1376-1385. doi:10.408/JCP.v6n106 PubMed (Pubitemid 41779535)
26. Vieta E, Reinares M, Corbella B, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001;21(5):469-473. doi:10.1097/04714-2010-02 PubMed (Pubitemid 32937427)
27. Vieta E, Bourin M, Sanchez R, et al. Aripiprazole Study Group. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187(3):235-242. doi:10.192/bjp.187.3.235 PubMed (Pubitemid 41306104)
28. Vieta E, Calabrese JR, Goikolea JM, et al. BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9(4):413-425.
29. Reed C, Novick D, Gonzalez-Pinto A, et al. Observational study designs for bipolar disorder-what can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):715-721.
30. Yen CF, Cheng CP, Huang CF, et al. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disord. 2008;10(5):617-624.
31. Johnson FR, Ozdemir S, Manjunath R, et al. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007;45(6):545-552.
32. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95-105. doi:10.102/hup.908 PubMed (Pubitemid 351359581)
33. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007; 89(1-3):91-100.
34. Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008;49(1):65-69. doi:10.1016/j.compsych. 207.08.02 PubMed (Pubitemid 350183965)
35. Kogan JN, Otto MW, Bauer MS, et al. STEP-BD Investigators. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 2004;6(6):460-469.
36. Marangell LB. The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry. 2004;65(suppl 10):24-27.